Mircea Dediu

Bucharest, B, Romania

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Lung Cancer in Romania.

Lung Cancer in Romania.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 02, 2024

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability.

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability.

Journal: BMC proceedings
Published: January 17, 2024

The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.

The Unmet Diagnostic and Treatment Needs in Large Cell Neuroendocrine Carcinoma of the Lung.

Journal: Current oncology (Toronto, Ont.)
Published: July 03, 2023

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT).

Journal: Current oncology (Toronto, Ont.)
Published: June 21, 2022

Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624].

Journal: Breast care (Basel, Switzerland)
Published: July 22, 2019

A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.

A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer.

Journal: Breast care (Basel, Switzerland)
Published: June 07, 2018

ESMO 2017-my personal highlights.

ESMO 2017-my personal highlights.

Journal: Memo
Published: January 26, 2018

My personal highlights of ESMO 2016.

My personal highlights of ESMO 2016.

Journal: Memo
Published: January 23, 2017

Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change.

Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology
Published: January 01, 2017

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.

Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 09, 2016

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: January 06, 2016

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

Journal: The Lancet. Oncology
Published: April 07, 2015
Showing 1-12 of 24

Last Updated: 09/26/2026